Drug Profile
Research programme: anti-IGF monoclonal antibodies - Shin Nippon Biomedical Laboratories
Alternative Names: m610.27; m67; m708.5Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Shin Nippon Biomedical Laboratories
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 14 Oct 2014 Preclinical trials in Cancer in USA (unspecified route)